Compare Vertiv Holdings Co (VRT) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertiv Holdings Co vs Viatris Inc — how do they compare? Vertiv Holdings Co trades at $305.01 (market cap $112.03B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Vertiv Holdings Co is far larger — about 5.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| VRT | VTRS | |
|---|---|---|
Market Cap | $112.03B | $19.79B |
Sector | Technology | Health |
52-Week High | $376.23 | $17.39 |
52-Week Low | $121.82 | $8.74 |
Enterprise Value | $112.80B | $32.00B |
Dividend Yield | 0.09% | 2.83% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
